LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
April 30, 2025 16:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO,…
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX)…
UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025
Data to be presented in Clinical Trials in Progress Session on Monday,…
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
April 26, 2025 10:00 ET | Source: Protara Therapeutics TARA-002 demonstrates 100%…
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
April 24, 2025 20:00 ET | Source: BriaCell Therapeutics Corp. PHILADELPHIA and…
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
April 24, 2025 01:00 ET | Source: Addex Therapeutics Geneva, Switzerland, April…
Antag Therapeutics expands senior team to support clinical progress
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”),…
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational…
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
April 16, 2025 08:00 ET | Source: Akari Therapeutics Plc Advancing development…
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”)…